CellX Biosolutions Company Profile

Background

Overview

CellX Biosolutions is a biotechnology startup founded in 2024 and headquartered in Zürich, Switzerland. The company specializes in developing innovative bacterial solutions for the sustainable treatment of industrial chemical pollutants. By harnessing the natural degradation capabilities of bacteria, CellX aims to provide eco-friendly alternatives to traditional chemical waste disposal methods, such as incineration.

Mission and Vision

CellX's mission is to revolutionize chemical waste management by leveraging nature's recyclers—bacteria—to address environmental challenges posed by hazardous industrial chemicals. The company's vision is to transform pollution into a manageable issue, offering scalable and sustainable solutions that align with global environmental goals.

Primary Area of Focus

The company's primary focus is on the biodegradation of persistent pollutants, including per- and polyfluoroalkyl substances (PFAS), pharmaceuticals, agrochemicals, and microplastics. By identifying and utilizing specific bacterial strains capable of degrading these substances, CellX aims to mitigate environmental contamination effectively.

Industry Significance

CellX operates within the environmental biotechnology sector, addressing the growing need for sustainable waste management solutions. The global market for hazardous chemical waste treatment is projected to reach USD 48 billion by 2027, driven by stricter environmental regulations and the increasing demand for eco-friendly practices. CellX's innovative approach positions it as a significant player in this expanding market.

Key Strategic Focus

Core Objectives

• Sustainable Pollution Treatment: Develop and deploy bacterial solutions that effectively degrade hazardous chemicals, reducing reliance on traditional, environmentally harmful disposal methods.

• Scalability and Efficiency: Create scalable and efficient bioremediation processes that can be implemented across various industrial settings, including wastewater treatment plants and chemical storage facilities.

• Regulatory Compliance: Ensure that all solutions meet international environmental standards and regulations, facilitating widespread adoption in industries with stringent compliance requirements.

Specific Areas of Specialization

• PFAS Degradation: Focus on the breakdown of PFAS compounds, known for their persistence in the environment and potential health risks.

• Pharmaceutical Waste Management: Address the challenges associated with the disposal of pharmaceutical by-products, offering sustainable alternatives to incineration.

• Agrochemical Remediation: Provide solutions for the degradation of agrochemicals, including pesticides and herbicides, to prevent soil and water contamination.

• Microplastic Degradation: Develop bacterial strains capable of degrading microplastics, contributing to the reduction of plastic pollution in aquatic ecosystems.

Key Technologies Utilized

• Microfluidic-Based Tool: Employ a novel microfluidic device to capture and isolate bacterial consortia with superior degradation capabilities from diverse environments.

• Bioremediation Cultures: Scale up identified bacterial strains into commercial products that can be applied directly in industrial settings for pollutant degradation.

Primary Markets Targeted

• Chemical Manufacturers: Offer solutions for the treatment of hazardous waste generated during chemical production processes.

• Pharmaceutical Companies: Provide methods for the disposal of pharmaceutical by-products in an environmentally responsible manner.

• Agricultural Sector: Assist in the remediation of agrochemical pollutants to protect soil and water resources.

• Environmental Remediation Services: Collaborate with companies specializing in environmental cleanup to implement bioremediation strategies.

Financials and Funding

Funding History

As of February 2025, CellX Biosolutions has secured a total of CHF 1.7 million in pre-seed funding. This capital is intended to accelerate the development of its bacterial solutions for PFAS degradation and to establish collaborations with industrial partners for real-world applications.

Recent Funding Rounds

• Pre-Seed Round (February 2025): Raised CHF 1.7 million, led by Positron Ventures, with additional support from Kickfund, Venture Kick, business angels Marcello Campanelli and Ian Metcalfe, and non-dilutive funding from the Stadt Zürich through the KlimUp program.

Notable Investors

• Positron Ventures: Led the pre-seed funding round, indicating strong confidence in CellX's innovative approach to environmental remediation.

• Kickfund: Provided additional support, reflecting a commitment to sustainable technology investments.

• Marcello Campanelli and Ian Metcalfe: Business angels who contributed to the funding, bringing valuable industry experience and networks.

• Stadt Zürich (KlimUp Program): Offered non-dilutive funding, demonstrating municipal support for green technology initiatives.

Intended Utilization of Capital

• Product Development: Enhance the scalability and efficiency of bacterial solutions for industrial applications.

• Partnerships: Establish collaborations with industrial partners to implement bioremediation solutions in real-world settings.

• Research and Development: Expand the library of bacterial strains capable of degrading a wider range of pollutants.

Pipeline Development

Key Pipeline Candidates

• PFAS-Degrading Bacteria: Develop bacterial strains capable of breaking down various PFAS compounds, addressing a significant environmental concern.

• Pharmaceutical Degraders: Isolate bacteria that can degrade specific pharmaceutical by-products, offering sustainable waste management solutions.

• Agrochemical Remediators: Identify bacterial strains effective in degrading pesticides and herbicides, preventing environmental contamination.

• Microplastic Degraders: Discover bacteria capable of breaking down microplastics, contributing to the reduction of plastic pollution in aquatic ecosystems.

Stages of Development

• Discovery Phase: Utilize microfluidic technology to capture and isolate bacterial consortia from diverse environments.

• Optimization Phase: Enhance the degradation efficiency of selected bacterial strains through laboratory processes.

• Scale-Up Phase: Develop commercial formulations of bacterial solutions for industrial applications.

Target Conditions

• PFAS Contamination: Address environmental pollution caused by PFAS compounds in water and soil.

• Pharmaceutical Waste: Provide solutions for the degradation of pharmaceutical by-products in wastewater.

• Agrochemical Pollution: Remediate soil and water contaminated with pesticides and herbicides.

• Microplastic Pollution: Reduce the presence of microplastics in aquatic environments through biological degradation.

Anticipated Milestones

• Pilot Projects: Initiate collaborations with industrial partners to implement bacterial solutions in real-world settings.

• Regulatory Approvals: Obtain necessary certifications and approvals for commercial deployment of bioremediation products.

• Market Expansion: Expand the range of pollutants addressed by CellX's bacterial solutions, broadening the company's impact on environmental remediation.

Technological Platform and Innovation

Proprietary Technologies

• Microfluidic-Based Tool: A patented device that enables the capture and isolation of bacterial consortia with superior degradation capabilities from diverse environments.

• Bioremediation Cultures: Commercial formulations of bacterial solutions designed for direct application in industrial settings, such as chemical storage reservoirs and wastewater treatment plants.

Significant Scientific Methods

• Bacterial Isolation: Employ microfluidic technology to identify and isolate bacterial strains capable of degrading specific pollutants.

• Biodegradation Optimization: Enhance the efficiency of bacterial degradation through laboratory processes, including genetic and environmental optimization.

• Scale-Up Processes: Develop methods to produce large quantities of bacterial cultures suitable for industrial applications.

AI-Driven Capabilities

While specific AI-driven capabilities are not detailed in the available information, CellX's innovative approach suggests potential integration of advanced technologies in their research and development processes.

Leadership Team

Executive Profiles

• Dr. Estelle Clerc (CEO): Holds a Ph.D. in microbiology from ETH Zurich. As CEO, she leads the strategic direction and overall operations of CellX Biosolutions.

• Geoffrey Besnier (COO): Co-founder and Chief Operating Officer, responsible for overseeing the company's operational activities and ensuring efficient execution of business strategies.

• Dr. Fabienne Kurt (CSO): Chief Scientific Officer, leading the scientific research and development efforts, focusing on the discovery and optimization of bacterial strains for pollutant degradation.

• Christian Engler (Engineering Lead): Responsible for engineering developments supporting product scale-up and operational infrastructure.